ArticleJournal of translational medicine2026
TROP2 confers resistance to oxidative stress-induced cancer cell death through YAP/HMOX1 signaling.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTrophoblast cell surface antigen 2 (TROP2) is overexpressed in non-small cell lung cancer (NSCLC) and associated with poor prognosis, yet its role in ferroptosis—an iron-dependent form of regulated cell death—remains largely unknown. This study investigated the function and underlying mechanism of TROP2 in ferroptosis regulation in lung cancer.
methodsTROP2 expression was examined in NSCLC tissues and cell lines. Functional assays, including RNA sequencing, qRT-PCR, Western blot, flow cytometry, and transmission electron microscopy, were performed in lung cancer cells with TROP2 knockdown or overexpression. The involvement of the YAP1/HMOX1 axis was evaluated using luciferase reporter assays, immunofluorescence, and nuclear-cytoplasmic fractionation. An in vivo xenograft model was established to assess the effect of TROP2 inhibition combined with the ferroptosis inducer RSL3.
resultsTROP2 was significantly upregulated in NSCLC tissues and correlated with worse patient survival. Knockdown of TROP2 sensitized cells to RSL3-induced ferroptosis, as evidenced by increased lipid peroxidation, reactive oxygen species, and malondialdehyde levels, along with reduced glutathione. Mechanistically, TROP2 inhibited nuclear translocation of YAP1, which consequently suppressed transcriptional activation of the key ferroptosis-promoting gene HMOX1. Rescue experiments confirmed that HMOX1 mediates the pro-ferroptotic effect of TROP2 knockdown. In vivo, TROP2 depletion synergized with RSL3 to suppress tumor growth and elevate ferroptosis markers.
conclusionTROP2 confers ferroptosis resistance in NSCLC by inhibiting YAP1 nuclear translocation and subsequent HMOX1 transcription. Targeting TROP2 sensitizes lung cancer cells to ferroptosis inducers, revealing a novel TROP2/YAP1/HMOX1 regulatory axis with therapeutic potential for NSCLC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.